Atrial fibrillation (AF) is the most common type of cardiac arrhythmia and it mainly affects the elderly population. AF often causes an pronounced decrease in quality of life and furthermore increases the risk of stroke. Existing drug therapies only have a limited effect and produces risks of serious adverse events. Therefore, there is a considerable need for developing better and safer drugs. Inhibition of SK channels constitute a novel and promising drug target for the treatment of AF, and Acesion Pharma aims to develop a first-in-class SK inhibitor for the acute cardioversion of AF.

Although not life threatening, IBS can seriously impair overall quality of life, and as a result it is one of the most common reasons for visits to primary care physicians and gastroenterologists.

Parkinson's disease and Schizophrenia are today treated with drugs that - to some extent - are able to eliminate the disease symptoms, but in turn result in highly annoying involuntary movements. These adverse effects, for which there is no good treatment, significantly reduce quality of life and can be so massive that the diseases cannot be optimally treated. Concit Pharma drugs will ameliorate movement disorders including those associated with treatment of Parkinson’s disease and Schizophrenia.

The market for fluorescence cell detection has high potential, with an annual growth of 15% and CytoTrack's inclination is to interact with major diagnostics companies to bring in this potential. CytoTrack is able to deliver results within thirty minutes. Previously processing times required up to several days.CytoTrack has engaged in selected collaborations with highly international cancer centres the resource-efficient solution will improve cancer therapy.

The pharmaceutical industry has largely stopped exploring conventional natural products. Natural structures are typically difficult to source, difficult to identify, difficult to analog and difficult to manufacture. However, Nature is still the most efficient supplier of long lasting healthcare ingredients. Evolva´s Watchmaker® technology creates new combinations of synthetic structured products leading to new compounds that interact with the most productive functionalities of natural products. By mixing millions of genes from multiple species such as sponges, humans & plants, Watchmaker® creates long lasting solutions for patients with lifelong conditions.Evolva is listed on the Swiss Stock Exchange as Evolva Holding SA.

Fluxome currently provides the two ingredients Reservatrol and PUFA Beta Glucan. Reservatrol is the nutritious ingredient in red wine believed to prevent cancer and increase life expectancy and Beta Glucan has a documented immune enhancing effect. Both ingredients are intended for use by the global food and dietary supplement industry.Fluxome Resveratrol has obtained Novel Foods Approval in Europe and the US. 

Based on their proprietary tools, unique knowledge, and ability to customize solutions to meet the need of each client, Intomics can improve biological and clinical research in areas such as biomarker discovery and optimization, extraction of biological knowledge from data, drug discovery and translational research. The advanced data analyses will enable the pharmaceutical industry to get the most out of trials and research in new drug candidate, so as to discover drug and diagnostic targets cheaper and faster.In a ten-year perspective, integrative approaches like Intomics will form the basis for advanced, quantitative and qualitative types of systems biology, where simulation and modelling will be a key for the understanding of complex diseases and their underlying causes at the molecular level.In 2010 Intomics entered into collaboration with Danish pharmaceutical company Leo Pharma. 

Musculoskeletal conditions are the most common causes of severe long-term pain and physical disability, affecting hundreds of millions of people across the world. The condition is increasingly treated by transplanting synthetic solutions that however does not adhere to the bone sufficiently well.

LeVoss will be able to deliver a transplant material that integrates more effectively with the bone while also providing conditions for new tissue generation.

It has become apparent that most chemotherapeutic drugs on the market have varied efficacy with varying genetic profiles. This poses a challenge for both the treatment with and the development of these drugs. MPI's technology will allow developers of chemotherapeutic drugs to speed up drug development by providing a genetic profile of the most relevant patients for the drug to be tested. This will save significant amounts in development cost as well as increase the possibility of success. Additionally oncologists will be able to use MPI's technology as a guide for selecting the most efficient chemotherapeutic drug or drug combinations for a specific patient.

The blockmir compounds being developed by Mirrx have relevance for all major disease areas and reduce the risk of unwanted side-effects dramatically, as compared to other compounds interfering with microRNA pathways. From the number of human genes estimated to be subject to microRNA-based regulation, approximately every third human gene may be targeted by a blockmir. In addition to the apparent applications as therapeutics, blockmirs will prove highly important research tools, pivotal to the understanding of microRNA based regulatory pathways and the contributions of single microRNA-mRNA interactions.

Oral mucositis is an adverse effect of cancer chemo- or radiotherapy, where the mucosal lining of the mouth becomes thin, may slough off and then become red, inflamed and ulcerated. The condition is very painful and will often result in patients having trouble speaking, eating, or even opening the mouth. Oral mucositis is the most common distressing and disabling acute complication of cancer chemotherapy and radiotherapy as reported by patients, and is a significant dose-limiting toxicity of cancer therapy. Pain and secondary infections associated with untreated oral mucositis result in substantial increases in hospitalization costs. Development of a new pain relief product for these patients will have a significant impact on quality of life and on the cost of care for cancer patients.

The Sense technology creates new possibilities for easy, comfortable, precise and continuous measurements of blood pressure. Unlike traditional inflatable cuff alternatives the technology enables patients to be monitored in natural situations with negligible discomfort.

The device will help increase productivity and reduce hands-on procedures in a user-friendly way.

The pharmaceutical industry has largely stopped exploring conventional natural products. Natural structures are typically difficult to source, difficult to identify, difficult to analog and difficult to manufacture. However, Nature is still the most efficient supplier of long lasting healthcare ingredients. Evolva´s Watchmaker® technology creates new combinations of synthetic structured products leading to new compounds that interact with the most productive functionalities of natural products. By mixing millions of genes from multiple species such as sponges, humans & plants, Watchmaker® creates long lasting solutions for patients with lifelong conditions.